Can mitochondrial stress be weaponized in cancer? Bantam starts BTM-3566 dosing
Bantam Pharmaceutical has treated the first patient with BTM-3566 in a Phase 1 clinical trial at the Princess Margaret Cancer Centre in Toronto. The study marks the first-in-human administration of the company’s lead investigational therapy, a first-in-class small molecule designed to treat aggressive cancers by modulating the OMA1-ATF4 integrated stress response pathway. This trial includes […]